Related Experiment Videos
[Clinical evaluation of cefpirome in children]
Insights
Cefpirome (CPR) demonstrated high efficacy in treating bacterial infections in children, with a 90.9% success rate. This antibiotic showed a favorable safety profile with minimal adverse effects observed in the clinical trial.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Antimicrobial Susceptibility Testing
Background:
- Bacterial infections pose a significant health risk in pediatric populations.
- The development of novel antibiotics is crucial for combating resistant pathogens.
- Cefpirome (CPR) is a cephalosporin antibiotic with potential utility in treating pediatric bacterial infections.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Cefpirome (CPR) in pediatric patients with bacterial infections.
- To determine the Minimum Inhibitory Concentrations (MICs) of CPR against clinically relevant bacterial isolates.
Main Methods:
- A clinical trial involving 11 pediatric patients (4 months to 11 years) with various bacterial infections.
- CPR administered intravenously at daily dosages of 55.5-91.7 mg/kg, divided into three doses.
- MICs of CPR were determined for 18 beta-lactamase producing bacterial strains isolated from patients.
Main Results:
- Cefpirome (CPR) achieved an overall efficacy rate of 90.9% (8 excellent, 2 good responses out of 11 patients).
- Adverse reactions were minimal, with only slight elevations in liver enzymes and mild leukopenia noted in two patients.
- CPR exhibited potent activity against a range of beta-lactamase producing bacteria, with MICs often below 0.025 µg/mL for strains like Klebsiella pneumoniae and Enterobacter cloacae.
Conclusions:
- Cefpirome (CPR) is an effective and well-tolerated antibiotic for treating bacterial infections in pediatric patients.
- The favorable safety profile and potent in vitro activity suggest CPR's value in pediatric infectious disease management.
- Further studies may be warranted to explore CPR's role in specific pediatric bacterial infection contexts.
Abstract:
Cefpirome (CPR, HR 810) was clinically evaluated for its efficacy and safety in 11 patients with ages from 4 months to 11 years with bacterial infection. The results obtained are summarized as follows. 1. CPR was administered to 6 patients with bronchopneumonia, a patient with pneumonia, a patient with tonsillitis, 2 patients with acute pharyngitis and a patient with suppurative parotitis at daily dosage levels ranging 55.5-91.7 mg/kg, divided into 3 using intravenous bolus injection or 30 minutes drip infusion. Clinical responses of the 11 patients were as follows: excellent; 8 patients, good; 2 patients, poor; 1 patient, hence the efficacy rate was 90.9%. 2. Neither clinical adverse reaction nor abnormal laboratory test value was observed except slight elevation of GOT and GPT in a patient and leukopenia in another. 3. MICs of CPR against 18 beta-lactamase producing strains isolated from patients were as follows. MIC against a strain of Staphylococcus aureus was 1.56 micrograms/ml, MICs against 3 strains of Klebsiella pneumoniae were less than 0.025 microgram/ml, those against 3 out of 5 strains of Enterobacter cloacae were less than 0.025 microgram/ml and those against the remaining 2 strains were 0.05 and 0.20 micrograms/ml. MICs against 2 out of 3 strains Acinetobacter lwoffi were 1.56 micrograms/ml, and that of the remaining 1 strain was 0.39 microgram/ml. MICs against 2 strains of Pseudomonas cepacia were 1.56 micrograms/ml. MICs against a strain of Pseudomonas putida and a strain of Citrobacter diversus were 0.78 and less than 0.025 microgram/ml, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)